Ovid Therapeutics Inc.
OVID · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $66,204 | $227,271 | $130,991 | $216,608 |
| - Cash | $26,301 | $27,042 | $44,868 | $187,798 |
| + Debt | $14,755 | $16,002 | $16,536 | $0 |
| Enterprise Value | $54,658 | $216,231 | $102,658 | $28,810 |
| Revenue | $566 | $392 | $1,503 | $208,383 |
| % Growth | 44.4% | -73.9% | -99.3% | – |
| Gross Profit | $566 | $392 | $1,503 | $208,383 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$57,772 | -$57,013 | -$54,166 | $124,447 |
| % Margin | -10,207.1% | -14,544.1% | -3,604.5% | 59.7% |
| Net Income | -$26,433 | -$52,339 | -$54,169 | $122,835 |
| % Margin | -4,670.1% | -13,351.8% | -3,604.7% | 58.9% |
| EPS Diluted | -0.37 | -0.74 | -0.77 | 1.76 |
| % Growth | 50% | 3.9% | -143.8% | – |
| Operating Cash Flow | -$55,956 | -$45,781 | -$55,227 | $118,612 |
| Capital Expenditures | -$71 | -$137 | -$1,419 | -$184 |
| Free Cash Flow | -$56,027 | -$45,918 | -$56,646 | $118,428 |